Chronic L2-Cmu treatment is well tolerated in older mice We next performed a 6 mo feasibility study with weekly L2-Cmu i.p
Injectable GLP-1-based therapies, including semaglutide and tirzepatide, have demonstrated substantial benefits for weight loss and cardiometabolic risk reduction ( 1 3 ), but real-world uptake has been shaped by factors such as route of administration, access, tolerability, and insurance coverage ( 4 7 )
Interestingly, lower levels of branched-chain amino acids (BCAAs) and keto acids in the blood have been linked to the effect of tirzepatide and LAGIPRA on insulin sensitivity
J., Vidyasagar, R., Evans, C
While semaglutide works on the GLP-1 pathway, tirzepatide uses GLP-1 and GIP to exert its effects